Summary of COVID-19 medicines guidance: Neurological disorders

This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to coronavirus and neurological disorders.

Our advice is constantly reviewed as the pandemic situation evolves.

Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.

To see our professional guidance summaries for other clinical areas, click here

Advice in this area includes:

The Society of British Neurological Surgeons: Clinical Guide for the management of neuro trauma patients

Last updated 19 March 2020

  • This guidance sets out some principles to ensure that essential neurotrauma care continues with the minimum burden on the NHS during the coronavirus pandemic.
  • It includes guidance on how to manage and prioritise the different types of neurotrauma patients, including a flow chart on managing cranial and spinal injury.

 

Association of British Neurologists: Guidance on the use of disease-modifying therapies in multiple sclerosis in response to the COVID 19 pandemic

Last updated 18 May 2020

  • Detailed guidance is provided on whether to initiate, continue or discontinue disease modifying therapies, based on the increased risk they may confer of viral infection
  • To conserve resource and reduce travel risk, advice is given regarding abbreviated blood monitoring.
  • Should a patient become infected with COVID-19, advice is provided in managing patients and their disease modifying therapies.
  • The recommendations have also been provided in a patient friendly format.

Administration update (10 November 2020): Editorial amendments only.